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Purpose. To evaluate hemodynamic parameters as possible predictors for glaucoma progression. Methods. An 18-month
randomized double-masked cohort study including 30 open-angle glaucoma patients receiving ﬁxed-combination treatment with
Dorzolamide/Timolol (DTFC) or Latanoprost/Timolol (LTFC) (n = 15 per group) was performed. Intraocular pressure (IOP),
arterial blood pressure (BP), ocular and diastolic perfusion pressures (OPP, DPP), color Doppler imaging, pulsatile ocular blood
ﬂow analysis, scanning laser polarimetry, and Humphrey visual ﬁeld evaluations were included. Results. Both treatments showed
statistically similar IOP reduction. Six patients in DTFC and 7 in LTFC group met glaucoma progression criteria. DTFC group had
higherOPP,DPP,andlowervascularresistivityindicesascomparedtotheLTFC.Progressingpatientshadhighernerveﬁberindex,
lower systolic BP, OPP, DPP, higher ophthalmic and central retinal artery vascular resistance, and lower pulse volume (P<. 05;
t-test). Conclusions. Structural changes consistent with glaucoma progression correlate with non-IOP-dependent risk factors.
1.Introduction
The recent series of large, multicenter, randomized clinical
trials examining glaucoma treatment provide some informa-
tion regarding current management goals for maintaining a
target intraocular pressure (IOP). However, in many cases,
glaucoma progression occurs despite maintaining target
IOP. For instance, in the Collaborative Normal-Tension
Glaucoma (CNTG) study, 12 to 18% of glaucoma patients
progressed despite a 30% IOP reduction [1]; in the Early
Manifest Glaucoma Trial (EMGT), 45% progressed despite
an average IOP reduction of 25% at 6-year followup [2].
Leske et al. [3] further reported that 67% of patients
progressed over 11 years of followup despite IOP reduction.
Non-IOP factors have also been identiﬁed as contribut-
ing to open-angle glaucoma (OAG) progression, including
lowerocularperfusionpressure(OPP),reducedocularblood
ﬂow, cardiovascular disease, and low systolic blood pressure.
Impaired optic nerve blood ﬂow is considered a potential
causative factor in the development of glaucoma optic
neuropathy [4, 5]. However, it remains unknown whether
manipulation of perfusion pressure, blood pressure, and
ocular blood ﬂow will prevent glaucoma progression.
The European Glaucoma Guidelines of 2008 [6]s e t
the preservation of visual function as the primary goal of
glaucoma therapy. In cellular terms, this can be interpreted
as prevention of retinal ganglion cell death. However, the
exact factors contributing to retinal ganglion cell death
remain speculative [7]. Although changes in ocular blood
ﬂow might be the consequence of IOP variations, they
can also be a primary physiological event [8]. As IOP
therapies may inﬂuence ocular perfusion [9], it is vital
to investigate glaucoma therapies for vascular interactions
in addition to IOP reduction. One possible therapy is
dorzolamide hydrochloride, a potent vasoactive glaucoma
topical treatment that many studies have shown to increase
various measures of ocular blood ﬂow [10–16]. Although
not all studies are in full agreement [17, 18], a recent2 Journal of Ophthalmology
meta-analysisofpublishedstudiesfoundcarbonicanhydrase
inhibitors,suchasdorzolamide,tobeconsistentlyeﬀectiveat
increasing the ocular circulation [19].
Much less research has been conducted to investigate
the eﬀects of a combination treatment on improving ocular
circulation and reducing IOP, especially in relation to glau-
coma progression. To our knowledge, there are no long-term
prospective double-blind studies that investigated the IOP
lowering eﬀects of ﬁxed combinations and the correlation
between ocular hemodynamic and both functional and
structural changes in glaucoma patients. This study investi-
gatestheﬁxedcombinationsofdorzolamide/timolol(DTFC)
and latanoprost/timolol (LTFC) on IOP lowering and glau-
coma progression while examining if baseline ocular blood
ﬂow parameters are predictive of glaucomatous progression
as determined by visual ﬁeld and/or structural changes.
2.MaterialsandMethods
Thirty OAG patients were followed for 18 months in an
observational cohort study. All subjects read and signed an
informedconsent,andthestudywasapprovedbytheKaunas
University of Medicine institutional review board. Inclusion
criteria: OAG patients with characteristic glaucomatous
visual ﬁeld loss, optic nerve head damage, and IOP not
adequately controlled with timolol maleate (BID). Exclusion
criteria: mean deviation worse than or equal to −12dB in
HumphreyVisualFields(HVFA)central24-2SITAStandard,
cup to disc ratio equal or greater than 0.9, history of eye
disease other than refractive error, orbital or ocular trauma,
history of renal or hepatic disease, asthma or respiratory
disease, allergy to either of the study medications, and preg-
nant or nursing women. After timolol baseline examination,
patients were randomly assigned to double masked ﬁxed
combination treatment: LTFC or DTFC. Examinations were
carried out in both eyes and the study eye was chosen
randomly. All study visits were scheduled at the same time
of day ±1 hour in order to avoid diurnal ﬂuctuations in IOP
and arterial BP.
Examinations were carried out at baseline, 1, 6, 12, and
18 months of treatment, including full ophthalmic examina-
tion, visual acuity, Goldmann IOP, central corneal thickness
(CCT) (OcuScan PXP Alcon Labs. Inc), Humphrey visual
ﬁeld examination (24-2 SITA Standard), and scanning laser
polarimetry (GDx VCC Laser Diagnostic Technologies Inc.,
San Diego, CA). In the scanning laser polarimetry scan
printout each color represents a diﬀerent probability of the
parameter being outside normal limits, with red having the
highest probability (P<. 005), followed by yellow (P<. 01),
light blue (P<. 02), and dark blue (P<. 05); green (P<. 05)
refers to normal limits.
Allpatients had5ormore visualﬁeldsandscanning laser
polarimetry scans for analysis. Glaucoma progression was
identiﬁed by (1) standard automated perimetry (SAP) as a
statistically signiﬁcant decrease from baseline examination
in the pattern deviation values. Deepening of an existing
scotoma was considered if two points in an existing scotoma
declined by ≥10dB. Expansion of an existing scotoma
was considered if two contiguous points adjacent to an
existing scotoma declined by ≥10dB. A new scotoma was
diagnosed if an alteration meeting the criteria for glau-
comatous visual ﬁeld defect occured in previously normal
visual ﬁeld location. Three or more locations with P<. 01
constituted a change of threshold sensitivity. (2) Progressive
optic disc change is determined by optic disc assessment by
ophthalmoscopy and scanning laser polarimetry. Advanced
Serial Analysis detected repeatable change on two consec-
utive scans compared with baseline images using thickness
map, and deviation map, deviation from reference map,
temporal-superior-nasal-inferior-temporal (TSNIT) graph
or a signiﬁcant change in slope of the summary parameter
chart. Each slope represented the change in RNFL thickness
per year, assuming a linear trend across the followup period
[3, 20–22].
Ocular blood ﬂow was evaluated with pulsatile ocular
blood ﬂow analyser POBF (Paradigm medical industries.
Inc.) and Color Doppler imaging (CDI) (Accuvix XQ. Medi-
sonCo.,LTD.Seoul,RepublicofKorea).Bloodﬂowvelocities
were measured in the ophthalmic (OA), central retinal
(CRA), and short posterior ciliary arteries (SPCA), with
a 7.5MHz linear probe calculating peak systolic velocity
(PSV), end-diastolic velocity (EDV), and resistive index (RI)
in each vessel. Vascular RI was originally described by Pour-
celot and is calculated as RI = (PSV − EDV)/PSV [23–26].
All patients’ data were collected in the Eye Clinic of
Kaunas Medical University (Lithuania). CDI readings were
performed by a Reading Center: the Glaucoma Research and
Diagnostic Laboratories in the Department of Ophthalmol-
ogy, Indiana University School of Medicine (USA).
3.StatisticalAnalysis
CDI presents 12 diﬀerent parameters with a coeﬃcient of
variation ranging from 1.7% to 18%, and the majority of
parameterspresentwithacoeﬃcientofvariationunder10%.
The coeﬃcient of variation for total RNFL thickness is 5%.
W i t has a m p l es i z eo f1 5i ne a c hg r o u p ,w eh a v ea tl e a s t9 0 %
power to detect a change as small as 8.5% with alpha level
0.05 in retrobulbar velocities and 4.2% in RNFL thickness.
The coeﬃcient of variation for POBF is 15% [24]. In this
analysis, we determined our sample size must be greater than
29.17 subjects to detect changes smaller than 9% in blood
ﬂow parameters. Changes in visual ﬁelds over time were
analyzed using Humphrey’s STATPAC software as described
in Materials and Methods.
Descriptive statistics were obtained for the resulting
measurements. In the event that signiﬁcance was achieved by
repeated ANOVA measurements, we applied the Fisher’s and
Bonferroni models. Changes in individual parameters were
examined by paired Student’s t-test. P values of P<. 05 were
considered statistically signiﬁcant. To test the hypothesis
that the mean diﬀerence between two measurements is zero,
Wilcoxon signed-ranks test was used. Changes in OBF and
glaucomatous optic neuropathy parameters (functional and
structural changes) were analyzed by Pearson’s correlation
analysis. Multivariate regression models were used to evalu-
ate potential risk factors for glaucoma progression: age, IOP,
systolic BP, diastolic BP, OPP, DPP, pulse volume, and RI ofJournal of Ophthalmology 3
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Figure 1: ROC curve—DPP at 18-month visit in progressing
glaucoma patients. ROC: Receiver operating characteristic.
retrobulbarvessels.ReceiverOperatingCharacteristic(ROC)
curves for progressing glaucoma patients were performed to
analyze the discriminating ability of possible vascular risk
factors.
4. Results
We examined 30 OAG patients (15 patients in each study
group) with a mean age of 58.13 (SD 8.6), including 5
males and 25 females. There were no statistically signiﬁcant
diﬀerences between baseline parameters of either treatment
group.
Both DTFC and LTFC had similar IOP lowering eﬀect
over 18 months of observation (P = .653; t-test). Baseline
systolic and diastolic BP were comparable between DTFC
and LTFC groups (P = 0.101 and P = 0.07, resp., t-test).
DTFC showed statistically signiﬁcantly higher OPP, SPP, and
DPP at 1, 6, and 18 months visits (Table 1).
CDI baseline retrobulbar blood ﬂow parameters were
similar between the two groups (P>. 05; t-test), except
for a statistically signiﬁcantly higher OA-PSV and CRA-EDV
in the LTFC group (Table 2). Both combination treatment
regimes increased retrobulbar blood ﬂow velocities com-
pared to baseline, though signiﬁcant changes from baseline
at the OA-PSV (P = .003), OA-EDV (P = .001), and
CRA-PSV (P = .001) were only seen in the DTFC group
at 1- and 12-month followup. Vascular RI were decreased
in the DTFC group, showing statistically signiﬁcantly lower
resistivity compared to the LTFC group in the CRA and
SPCA during 12- and 18-month visits (Table 2). CRA-PSV
correlated with OA-PSV (r = 0.505;P = .004) and OA-EDV
(r = 0.450; P = .013), and SPCA-EDV correlated with DBP
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Figure 2: ROC curve—OPP at 18-month visit in progressing
glaucoma patients. ROC: Receiver operating characteristic.
(r = 0.454; P = .012), DPP (r = 0.449; P = .013), and
OA-RI (r =− 0.432; P = .017).
Average IOP, pulse amplitude, and POBF were not
statisticallydiﬀerentbetweentreatmentarms(Table 3).Pulse
volume increases in the DTFC group and diﬀerences at the
12- and 18-month visits when compared to the LTFC group
were signiﬁcant (P = .025 and P = .054, resp.).
Glaucoma progression was identiﬁed in 13 eyes (21.7%):
4 (6.7%) exhibiting structural changes, 1 (1.7%) with
perimetric changes, and 8 (13.3%) showing both perimetric
and structural changes. There were no statistically signiﬁcant
diﬀerences in IOP between progressing and stable glaucoma
patients at the ﬁnal visit (Table 4). Progressing glaucoma
patients had higher OA RI, lower SPCA-EDV (P<. 05; t-
test), and decreased pulse volume by 2.68 (SD 0.61)μL( P =
.0001; t-test) as compared to stable glaucoma patients at the
18-month visit. Progressing glaucoma cases had signiﬁcantly
lower SBP, OPP, and DPP (Table 4).
Changes in TSNIT correlated with SBP (r = 0.614; P =
.025) in progressing glaucoma patients. The odds of higher
NFI at the ﬁnal 18-month visit was 13.82 times greater (95%
CI 1.32–143.76) in patients with baseline CRA RI ≥ 0.67
(P = .028) and older age patients (95% CI 0.90–0.99) (P =
.021).
The area under the Receiver Operating Characteristic
(ROC) curve in progressing glaucoma patients with DPP <
62mmHg was 0.74 (95% CI lower bound 0.56; upper bound
0.919; P = .027) (Figure 1); the sensitivity and speciﬁcity
were 0.385 and 0.941, respectively. Progressing glaucoma
patients with OPP < 52mmHg had an area under the ROC
curve of 0.72 (95% CI lower bound 0.54; upper bound 0.907;
P = .038) (Figure 2); the sensitivity and speciﬁcity were4 Journal of Ophthalmology
Table 1: Comparison of characteristics of patients treated with DTFC and LTFC.
Characteristics DTFC LTFC P value
(t-test)
Age 56.93 (9.54) 59.33 (7.7) .455
CCT (μ) 548.03 (39.86) 549.65 (41.71) .914
C/D ratio 0.62 (0.14) 0.65 (0.15) .576
SBP mmHg baseline 157.70 (14.90) 146.70 (20.22) .101
1m o n t h 152.73 (16.90) 136.00 (13.67) .006∗
6m o n t h s 161.80 (18.40)∗ 146.800 (15.40)∗ .022∗
12 months 148.500 (11.18) 144.200 (17.41) .428
18 months 158.63 (14.24) 141.10 (15.21) .003∗
DBP mmHg baseline 92.13 (8.12) 86.80 (7.53) .073
1m o n t h 93.73 (15.41) 81.10 (7.04) .009∗
6m o n t h s 97.43 (12.19)∗ 86.87 (9.49)∗ .013∗
12 months 91.07 (8.47) 86.57 (9.10) .172
18 months 88.80 (5.81) 83.83 (8.41) .070
IOP mmHg baseline 22.10 (2.69) 20.57 (3.25) .171
1m o n t h 16.33 (2.11) 14.90 (2.69) .116
6m o n t h s 16.17 (2.81) 14.70 (2.57) .147
12 months 17.10 (2.42) 15.13 (3.42) .080
18 months 16.17 (2.08) 15.70 (3.38) .653
OPP mmHg baseline 53.8933 (5.61) 50.6100 (7.52) .186
1m o n t h 59.27 (9.70)∗ 51.47 (4.6)∗ .011∗
6m o n t h s 62.93 (8.98)∗ 56.33 (5.84)∗ .024∗
12 months 56.38 (6.19) 55.38 (6.92) .683
18 months 57.56 (3.81) 52.18 (7.26) .019∗
SPP mmHg baseline 135.60 (7.40) 126.13 (10.51) .008∗
1m o n t h 136.40 (12.1) 121.10 (7.5) .003∗
6m o n t h s 145.63 (19.6) 132.10 (8.4) .020∗
12 months 131.4 (8.25) 129.07 (10.24) .498
18 months 142.46 (7.4) 125.40 (9.34) .0001∗
DPP mmHg baseline 70.03 (7.40) 66.23 (8.11) .191
1m o n t h 77.20 (15.12)∗ 66.73 (5.35)∗ .021∗
6m o n t h s 81.33 (12.19)∗ 71.67 (7.95)∗ .016∗
12 months 73.97 (8.41) 71.43 (8.90) .430
18 months 72.97 (6.15) 66.03 (11.03) .045∗
∗P<. 05 statistically signiﬁcant.
DTFC:dorzolamide/timololﬁxedcombination;LTFC:latanoprost/timololﬁxedcombination;CCT:centralcornealthickness;C/Dratio:clinicallydetermined
cup-discratio;SBP:systolic blood pressure; DBP: diastolicblood pressure; IOP:intraocular pressure; OPP: ocular perfusion pressure; DPP:diastolic perfusion
pressure.
0.385and0.941,respectively.Inouranalysis,wefoundpower
0.88 with type I error of 0.05 and, although sensitivity was
low at cut oﬀ, the speciﬁcity was high.
5. Discussion
This observational cohort study showed that despite the
IOPloweringeﬀectwithdiﬀerentﬁxedcombinations(DTFC
and LTFC), 13 eyes (21.7%) were considered as progressing
glaucoma during 18 months of observation. Among patients
with progressing glaucoma, 6 were with DTFC and 7 with
LTFC treatment and showed no statistically signiﬁcant
hypotensive eﬀect between the two ﬁxed combinations.
Evidence shows that despite a wide range of glaucoma
therapyoptionstoreduceIOP,itisstilldiﬃcultinsomecases
to control slowly progressing optic neuropathy. During our
18-month observation, no cases of intolerance were found
and all patients completed the study.
Previously, Siesky et al. [27] reported that DTFC
increased ocular blood ﬂow in OAG patients while attain-
ing a similar IOP reduction compared to a treatment of
latanoprost plus timolol. Visual function, as expected, was
not diﬀerent in this short-term comparison. Evidence of
decreased optic nerve blood ﬂow correlating with visual ﬁeldJournal of Ophthalmology 5
Table 2: Color Doppler imaging parameters during 18 months of followup.
Characteristics DTFC LTFC P value
(t-test)
OA PSV (cm/s)
Baseline 23.79 (8.837) 30.86 (9.30) .042
1 month 37.10 (12.33) 36.04 (7.83) .781
6 months 38.15 (16.24) 33.87 (8.27) .371
12 months 40.66 (15.51) 42.50 (14.01) .736
18 months 33.70 (10.05) 28.71 (6.93) .125
OA EDV (cm/s)
Baseline 4.82 (2.47) 7.03 (3.60) .06
1 month 8.22 (4.22) 8.78 (3.94) .710
6 months 8.87 (6.03) 7.66 (2.52) .479
12 months 10.59 (4.79) 9.63 (5.11) .599
18 months 9.47 (6.19) 7.23 (4.54) .268
OA RI
Baseline 0.79 (0.11) 0.76 (0.11) .437
1 month 0.79 (0.07) 0.75 (0.11) .158
6 months 0.76 (0.11 ) 0.76 (0.09) .986
12 months 0.72 (0.12) 0.82 (0.17) .046∗
18 months 0.76 (0.10) 0.87 (0.28) .189
CRA PSV (cm/s)
Baseline 15.09 (3.78) 17.91 (7.80) .218
1 month 17.78 (4.43) 18.59 (7.34) .716
6 months 19.08 (7.59) 17.67 (5.95) .575
12 months 28.88 (13.40) 22.71 (12.82) .208
18 months 18.69 (8.79) 17.46 (5.24) .645
CRA EDV (cm/s)
Baseline 4.56 (1.81) 6.33 (2.48) .034∗
1 month 6.49 (2.22) 5.41 (3.19) .291
6 months 6.0 (2.49) 6.16 (2.64) .868
12 months 7.56 (3.67) 10.31 (7.34) .204
18 months 5.66 (2.80) 6.85 (3.24) .289
CRA RI
Baseline 0.80 (0.26) 0.81 (0.25) .915
1 months 0.68 (0.08)∗ 0.80 (0.16)∗ .011∗
6 months 0.65 (0.082) 0.72 (0.19) .192
12 months 0.74 (0.19) 0.85 (0.19) .000∗
18 months 0.67 (0.09) 0.93 (0.23) .000∗
SPCA PSV (cm/s)
Baseline 15.55 (4.70) 14.50 (6.59) .606
1 month 15.95 (5.91) 13.38 (3.10) .147
6 months 20.03 (6.42) 17.92 (3.68) .280
12 months 21.01 (10.40) 19.81 (7.04) .715
18 months 13.69 (5.45) 11.03 (2.83) .104
SPCA EDV (cm/s)
Baseline 4.42 (2.29) 14.50 (6.59) .973
1 month 4.69 (2.28) 3.31 (2.11) .095
6 months 6.10 (2.16) 5.47 (2.22) .442
12 months 6.04 (2.67)∗ 3.43 (2.26)∗ .007∗
18 months 4.39 (1.85) 3.87 (1.17) .366
SPCA RI
Baseline 0.71 (0.06) 0.79 (0.28) .232
1 month 0.75 (0.08) 0.79 (0.10) .229
6 months 0.69 (0.06) 0.69 (0.11) .969
12 months 0.70 (0.07)∗ 0.90 (0.27)∗ .011∗
18 months 0.69 (0.11)∗ 0.85 (0.30)∗ .015∗
∗P<. 05 statistically signiﬁcant.
DTFC: dorzolamide/timolol ﬁxed combination; LTFC: latanoprost/timolol ﬁxed combination; OA: ophthalmic artery; CRA: central retinal artery; SPCA:
short posterior ciliary artery, PSV: peak systolic velocity; EDV: end diastolic velocity; RI: resistive index.6 Journal of Ophthalmology
Table 3: Pulsatile ocular blood ﬂow parameters.
Characteristics DTFC LTFC P value
IOP average (mmHg)
baseline 19.58 (3.68) 20.96 (3.78) .320
1 month 17.12 (3.25) 18.01 (2.83) .429
6 months 17.67 (3.73) 17.71 (3.17) .975
12 months 17.87 (3.59) 16.48 (2.56) .231
18 months 16.10 (2.78) 15.23 (4.61) .539
Pulse amplitude
Baseline 4.17 (1.50) 4.73 (1.58) .335
1 month 3.91 (0.88) 3.95 (1.18) .917
6 months 4.93 (1.88) 4.12 (1.47) .201
12 months 4.75 (1.40) 4.67 (1.74) .891
18 months 4.73 (2.78) 4.51 (1.42) .675
Pulse volume (μL)
Baseline 7.19 (2.36) 7.81 (2.68) .507
1 month 7.99 (2.27) 7.60 (2.40) .648
6 months 8.91 (2.23) 7.07 (3.26) .417
12 months 9.25 (1.95)∗ 6.93 (3.20)∗ .025∗
18 months 9.29 (2.39)∗ 7.82 (1.55) .054∗
POBF Baseline (μL/s)
Baseline 16.81 (4.53) 17.57 (6.13) .702
1 month 19.12 (4.45) 18.52 (5.48) .754
6 months 19.43 (4.54) 18.63 (6.21) .69
12 months 20.87 (4.45) 18.43 (6.51) .242
18 months 21.33 (2.74) 19.75 (5.61) .336
∗P<. 05 statistically signiﬁcant.
DTFC: dorzolamide/timolol ﬁxed combination; LTFC: latanoprost/timolol ﬁxed combination; IOP: intraocular pressure; POBF: pulsatile ocular blood ﬂow.
damage has been reported in glaucoma patients [28–33]. In
our study, we report diﬀerences in OPP and DPP between
DTFC and LTFC; however, no signiﬁcant diﬀerences were
observed between LTFC and DTFC in terms of glaucoma
progression during the 18-month followup.
Previous studies examining ocular blood ﬂow and glau-
coma progression reported structural abnormalities [34]
preceding visual ﬁeld damage. Hafez et al. [35] also con-
cluded that rim perfusion might be reduced before mani-
festation of visual ﬁeld defects. Several studies have shown
abnormal retrobulbar vasculature in eyes with Glaucoma-
tous Optic Neuropathy (GON) [36–40]. Satilmis et al. [41]
showed that progression rate of glaucomatous visual ﬁeld
damage correlates with retrobulbar hemodynamic variables.
Zeitz et al. [42] further showed that progressive glaucoma
is associated with decreased blood ﬂow velocities in the
small retrobulbar vessels supplying the optic nerve head.
We found increased blood ﬂow velocities with combination
treatment as compared to timolol baseline. DTFC arm
had statistically signiﬁcantly lower baseline OA-PSV and
CRA-EDV as compared to LTFC baseline. After 1, 6, 12,
and 18 months of combination treatment, the velocities
in retrobulbar vessels increased as compared to baseline,
but diﬀerences in velocities between two treatment arms
were not statistically signiﬁcant. In our study, SPCA-EDV
was lower in progressing glaucoma patients as compared to
stable glaucoma patients. We found statistically signiﬁcant
diﬀerences in RIs between the two treatment cohorts. DTFC
showed statistically signiﬁcant decrease in CRA and SPCA
RIs at 12- and 18-month visits as compared to LTFC. Nielsen
and Nyborg [43]f o u n dt h a tP GF 2 α induces constriction in
isolated bovine aqueous veins. Remky et al. [44]r e p o r t e d
that reduction in retinal vessel diameters may account for
an increase in retinal vascular resistance. An increase in
vascular resistance might be related to vasoconstriction or
vasospasm, vasosclerosis, reduction of the vessel diameters,
or rheological factors leading to decreased volumetric ﬂow.
In our study, POBF that measures pulse volume was
signiﬁcantly higher in DTFC at 12 and 18-month visits
compared to LTFC. Progressing glaucoma patients had 2.675
(SD 0.61)μL lower pulse volume when compared to stable
glaucoma cases (P = .0001). Our results indicate DTFC
indeed increases markers of ocular blood ﬂow and perfusion
comparedtoLTFCbutwithnodiﬀerenceinpossiblemarkers
of glaucoma progression during the followup period. Longer
durationstudiesmayberequiredtodiﬀerentiateanypossible
(or lack thereof) ocular blood ﬂow beneﬁts.
The Beaver Dam study reported a positive correlation
between systolic BP and IOP [45]. The Los Angeles Latino
Eye Study [46] showed high systolic BP, low diastolic BP,
and low OPP as risk factors for glaucoma progression.
Data from EMGT [3]p o i n t e dt ol o ws y s t o l i cB Pa sa
long-term predictor for glaucoma progression. Further, data
from Thessaloniki Eye study [47] suggested BP status as an
important independent factor initiating optic disc changes
and/or as a contributing factor to glaucoma damage. In
our study, we found no ﬂuctuations or rise in IOP, but
OPP and DPP at 1, 6, and 18-month visits were statisticallyJournal of Ophthalmology 7
Table 4: Comparison of means between progressing and stable glaucoma patients at 18 months visit.
Parameter at 18 month Mean in stable glaucoma patients
(St. deviation)
Mean in progressing glaucoma patients
(St. deviation)
P value
(t-test)
IOP 15.32 (2.46) 16.73 (3.04) .171
IOP/POBF 14.73 (3.5) 16.88 (3.89) .123
MD (dB) −1.06 (2.30) −2.01 (2.13) .257
PSD (dB) 2.05 (2.53) 2.90 (2.41) .360
TSNIT (μ) 53.59 (5.28) 50.96 (7.10) .254
NFI 23.82 (2.36) 27.69 (3.29) .0008∗
SBP (mmHg) 151.50 (14.04) 147.73 (20.66) .55
DBP (mmHg) 88.44 (6.42) 83.53 (8.23) .077
OPP (mmHg) 57.19 (4.73) 51.84 (7.00) .019∗
DPP (mmHg) 73.06 (6.57) 64.85 (8.82) .007∗
OA PSV 32.26 (3.15) 29.82 (3.28) .048
OA EDV 9.19 (4.98) 7.25 (2.01) .197
OA RI 0.74 (0.07) 0.90 (0.07) <.0001∗
CRA PSV 19.96 (7.36) 15.61 (6.28) .099
CRA EDV 6.66 (3.19) 5.73 (2.85) .415
CRA RI 0.79 (0.08) 0.815 (0.06) .35
SPCA PSV 13.08 (5.11) 11.42 (3.43) .321
SPCA EDV 4.73 (1.71) 3.34 (0.83) .011∗
SPCA RI 0.77 (0.20) 0.76 (0.20) .893
AMPLITUDE 4.62 (1.48) 4.62 (1.44) .985
PULSE VOLUME 9.71 (2.01) 7.03 (1.00) .0001∗
POBF 21.25 (4.22) 19.60 (4.60) .316
DTFC: dorzolamide/timolol ﬁxed combination; LTFC: latanoprost/timolol ﬁxed combination; MD: mean deviation; PSD: pattern standard deviation; TSNIT:
temporal, superior, nasal, inferior, temporal average; NFI: nerve ﬁber index. POBF: pulsatile ocular blood ﬂow.
signiﬁcantly higher in the DTFC group. The LTFC group had
lower SBP at 1, 6, and 18-month visits and diastolic BP at
1 and 6 month visits (P<. 05; t-test). Progressing patients
had statistically signiﬁcantly lower systolic BP, OPP, and
DPP when compared to stable glaucoma cases. Calculating
the magnitude of changes in OPP and DPP parameters
compared to baseline values, we found them to be decreasing
in 69.2% of progressing glaucoma cases. Our calculated
sensitivity of decreased DPP was 0.7 and speciﬁcity 0.8.
BP and ocular perfusion pressure tend to exhibit ﬂuc-
tuations during the day and night. Importantly, Choi et
al. [48] reported that mean BP and OPP ﬂuctuations were
associated with reduced TSNIT and increased NFI. In our
study,BPwasmeasuredatthesametimeofthedayduringall
visits and statistically signiﬁcant diﬀerences in BP and OPP
parameters were seen at 1, 6, and 18 months but were not
signiﬁcant at 12 months between the two treatment groups.
TheLTFCgroupshowedlowerOPPandDPPandhigherNFI
as compared to DTFC at the 18 month visit (mean diﬀerence
7.80 (SD 3.69) (P = .046). Accordingly, progressing
glaucoma patients showed lower OPP and DPP and higher
NFI (mean diﬀerence 8.87 (SD 3.94)); P = .056). Yet,
despitediﬀerencesinthenonpressure-relatedparameters,we
found no diﬀerence in the percent of progression between
the treatment groups. In addition, we also found a strong
positivecorrelationbetweenTSNITaverageandBPandOPP
parameters at 18-month visit. Interestingly, low OPP and
DPPinprogressingglaucomapatientshadlowsensitivitybut
rather high speciﬁcity. In our analysis, statistically signiﬁcant
Area Under ROC Curve (AUC) values were reported at 0.74
and 0.72. While signiﬁcant, these values should be further
validated with a larger sample allowing for stratiﬁcation into
classiﬁed percentile ranges. The odds of higher NFI at the
ﬁnal 18-month visit was nearly 14 times greater in patients
with higher than 0.67 baseline CRA RI (P = .028) and older
age (P = .021).
Current glaucoma medications are targeted to decrease
the IOP and are not targeted to treat other hemodynamic
parameters. In our study, we found some diﬀerences in
structuraloutcomesbetweenthetwocombinationtreatment
regimes and according diﬀerences in BP, OPP, CRA, and
SPCA RIs. Our study is a preliminary study and the data
presented needs to be interpreted with caution. Increased
resistance to ﬂow in small retrobulbar vessels supplying the
optic nerve is probably related to glaucoma progression,
although this requires conﬁrmation in larger longitudinal
studies.
Possible limitations of the current study include the
diﬃculty in deﬁning glaucoma progression and speciﬁc
limitations in each imaging technology used to assess ocular
blood ﬂow. We have matched markers of possible glaucoma
progression, which may indicate but not actually represent8 Journal of Ophthalmology
glaucomatous progression. While the parameters may be
associated with progression, they are not necessarily good
in predicting progression. A risk factor must be strongly
associated with a disorder to be a worthwhile screening test,
and it is not unusual for a strong risk factor to fail to be
a good screening tool. Larger group studies with longer
followup, standardization of measurement techniques for
glaucoma progression, and ocular blood ﬂow parameters
are required to elicit a clear understanding of vascular risk
factors in glaucoma progression.
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